Evoke Pharma Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Evoke Pharma Inc Announces Closing of Initial Public Offering of 2,100,000 Shares of Common Stock
Evoke Pharma Inc announced the closing of its previously announced initial public offering of common stock. The Company sold a total of 2,100,000 shares of its common stock, at an initial public offering price of $12.00 per share. The gross proceeds to Evoke Pharma from the initial public offering were $25,200,000, before underwriting discounts and commissions and estimated offering expenses. Evoke Pharma has granted the representative of the underwriters a 30 day option to purchase up to 315,000 additional shares of common stock from the Company to cover over-allotments, if any. Aegis Capital Corp. acted as sole book-running manager for the offering. Cantor Fitzgerald & Co. and Feltl and Company, Inc. acted as co-managers for the offering. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 24, 2013.
Latest Key Developments in Pharmaceuticals
- Share this
- Digg this